NEEDHAM, Mass.--(BUSINESS WIRE)-- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that the Company will be presenting at the Cancer Immunotherapy: A Long-Awaited Reality conference taking place on October 21, 2010, at the New York Academy of Medicine in New York.
Thomas Davis, M.D., Senior Vice President and Chief Medical Officer, will provide an overview of the Company’s Precision Targeted Immunotherapy Platform. Dr. Davis is scheduled to present at 1:45 pm EDT. Additionally, Tibor Keler, Ph.D., Senior Vice President and Chief Scientific Officer, will participate in a panel discussion titled “Autologous versus Allogeneic Immunotherapy” at 2:45 pm EDT.
There will be a corresponding live webcast of the conference, which can be accessed by visiting http://www.mdbpartners.com/vaccine.
Hosted by MD Becker Partners and BioBusiness.TV, the Cancer Immunotherapy: A Long-Awaited Reality conference includes keynote speakers, panelist and plenary sessions, company presentations, and intimate networking opportunities to meet the needs of all attendees. Pre-registration is required and attendance is limited to 150 individuals; no walk-ins. To register, or to obtain more information, please visit http://www.mdbpartners.com/vaccine or contact MD Becker Partners directly at [email protected].
About Celldex Therapeutics, Inc.
Celldex Therapeutics is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates. For more information, please visit http://www.celldextherapeutics.com.
About MD Becker Partners
MD Becker Partners is a boutique management and strategy consulting firm focusing on both public and private companies in the life sciences industry. The firm also works with venture capitalists, institutional investors, and others that provide capital to these companies. As a strategic advisor and partner, MD Becker Partners provides a full range of services to help its clients increase visibility, unlock stakeholder value, and access resources to grow their business. To accomplish this, the firm integrates relations, strategy, and operational capabilities and applies them to carefully conceived and expertly enacted tactics. For more information visit http://www.mdbpartners.com.
BioBusiness.TV is the first independent Internet TV Network for Life Sciences Investors and Executives. The company creates video-based, industry focused business news and analysis programs. BioBusiness.TV produces and syndicates videos ranging from news and stock picks, to equity analyst insights, as well as C-level executive interviews on strategy, management, policy, marketing, science, and more. BioBusiness.TV’s latest Original Series, “The Stem Cell Review,” is a 10-part TV program on the science, medical applications, and business of stem cells, which provides a clear and concise understanding of the state of stem cells today, with the additional depth and expertise you would come to expect from the most renowned authorities in the field. For more information, visit http://www.biobusiness.tv.
Celldex Therapeutics, Inc.
Anthony S. Marucci, 781-433-0771
President and CEO
Celldex Therapeutics, Inc.
Avery W. Catlin, 781-433-0771
Chief Financial Officer
BMC Communications Group
Matthew Driscoll, 212-477-9007 x20
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Oncology Pharmaceutical Other Health Research Science